Olanib 150mg

Description of Olanib 150mg (Olaparib 150mg)

Olanib 150mg (Olaparib 150mg) is a type of targeted therapy called a PARP (oral poly (adenosine diphosphate–ribose) polymerase inhibitor)which has promising anti neoplasticaction in patients with metastatic breast cancer and a germline BRCA mutation.

Olanib 150mg (Olaparib 150mg) is an enzyme included in DNA repair and will act against cancers in people with hereditary BRCA1 or BRCA2 mutations, which involve some ovarian, breast and prostate cancer

Olanib 150mg (Olaparib 150mg) is a prescription Medicine which used under the supervision of medical practioners

Medical use /Indication of Olanib 150mg (Olaparib 150mg)

Olanib 150mg (Olaparib 150mg) is used for the treatment in patients with first line maintenance BRCAm advanced ovarian cancer

Olanib 150mg (Olaparib 150mg) is used for the treatment in patients with maintenance recurrent ovarian cancer.

Olanib 150mg (Olaparib 150mg) is used for the treatment in patients withadvanced gBRCAm ovarian cancer

Olanib 150mg is indicated for the treatment in patients with HER2 – negative metastatic breast cancer.

Mechanism of Action Olanib 150mg (Olaparib 150mg)

Olaparib belongs to targeted therapy. Olaparib is also called as poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, involving PARP1, PARP2, and PARP3. PARP enzymes are containing in DNA transcription, cell cycle regulation, and DNA repair.
Olaparib belongs to potent oral PARP inhibitor which induces synthetic fatality in BRCA 1/2 deficient tumor cells via the formation of double-stranded DNA cutsthat cannot be accurately repaired, which causesdivision of cellular homeostasis and cell death

Absorption of Olanib 150mg (Olaparib 150mg)

Maximum plasma concentration 1 to 3 hours

Distribution of Olanib 150mg (Olaparib 150mg)

volume of distribution 167 +/-196 L, plasma protein binding is 82%

Metabolism of Olanib 150mg (Olaparib 150mg)

Primarily metabolised by CYP3A4

Elimination of Olanib 150mg (Olaparib 150mg)

Excreted through the urine 44% and 42% through the feces.

Half – life of olanib 11.9 hours

Side effects of Olanib 150mg (Olaparib 150mg)

Common side effects for patients taking Olaparib :

• Decreased white blood cell count
• Abdominal pain
• Vomiting
• Upper respiratory tract infection
• Anemia
• Decreased neutrophils
• Musculoskeletal pain
• Diarrhea
• Decreased platelet count
• Decreased Haemoglobin
• Nausea
• Fatigue (including weakness)
• Increased serum creatinine
• Myalgia
• Headache
• Skin rash
• Back pain
• Taste changes
• Cough
• Swelling
• Dizziness
• Constipation
• Urinary tract infection
• Heartburn
• loss of appetite
• Shortness of breath

Precautions of Olanib 150mg (Olaparib 150mg)

• Haematological toxicity will cause in patients treated with Olanib contain diagnoses or findings of generally mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia.
• When olanib monotherapy administrated to patient the incidence of myelodysplastic syndrome will occur. • On basis of mechanism of action (PARP inhibition), olanib could cause risk to fetal when administered to a pregnant woman.
• Olanib combination with strong or moderate CYP3A inhibitors is not recommended.

Drug interaction of Olanib 150mg (Olaparib 150mg)

Concomitant use with myelosuppressive anticancer agents contains DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.

Combination of strong CYP3A inhibitors (itraconazole, telithromycin, clarithromycin,) will increase Olaparib plasma concentration.

Olanib combination with strong CYP3A inducers (itraconazole, telithromycin, clarithromycin,) will decrease Olaparib plasma concentration.

Pregnancy of Olanib 150mg (Olaparib 150mg)

Based on Olanib 150mg mechanism of action, the Medicine causes risk to the fetal may occur when administrated to a pregnant woman.

Lactation of Olanib 150mg (Olaparib 150mg)

Avoid breast feeding during the treatment with Olanib 150mg (Olaparib 150mg)

Dosage of Olanib 150mg (Olaparib 150mg)

Ovarian cancer :

Maintenance treatment of recurrent ovarian cancer

The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID

Continue treatment until disease progression or unacceptable toxicity

Monotherapy for advanced BRCA – mutated ovarian cancer

The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID

The capsules usual dose is 400mg (eight 50mg- mg capsules) PO BID

Continue treatment until disease progression or unacceptable toxicity.

Maintenancetreatment for advanced BRCA-mutated ovarian cancer

The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID

Follow the treatment until disease progression, undesirable toxicity or completion of 2 years of treatment

Finishing of 2 years of treatment

• Patients with full response (no radiologic evidence): discontinue treatment
• Patients with indication of disease and may asset from continuous treatment: cure beyond 2 years.

Storage of Olanib 150mg (Olaparib 150mg)

Store at 20℃ to 25℃

Missed dose of Olanib 150mg (Olaparib 150mg)

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule.
Consult doctors regarding missed dose.